2631-77-8

Basic information

• Product Name: 3,5-DIIODOSALICYLALDEHYDE
• Synonyms: 3,5-DIIODOSALICYLALDEHYDE;3,5-DIIODO-2-HYDROXYBENZALDEHYDE;AKOS BBS-00003265;2-HYDROXY-3,5-DIIODOBENZALDEHYDE;Benzaldehyde, 2-hydroxy-3,5-diiodo-;3,5-Diiodo-2-hydroxybenzaldehyde~2-Hydroxy-3,5-diiodobenzaldehyde;3,5-Diodosolicylaldehyde;3,5-Diiodo-4-Hydroxybenzaldhyd
• CAS NO: 2631-77-8
• Molecular Formula: C7H4I2O2
• Molecular Weight: 373.91
• EINECS: 220-117-2
• Product Categories: Aromatic Aldehydes & Derivatives (substituted);Aldehydes;C7;Carbonyl Compounds
• Mol File: 2631-77-8.mol
• Article Data: 69

Chemical Properties

• Melting Point: 109-110 °C(lit.)
• Boiling Point: 304.6 °C at 760 mmHg
• Flash Point: 138 °C
• Appearance: pale yellow powder
• Density: 2.602 g/cm³
• Vapor Pressure: 0.000481mmHg at 25°C
• Refractive Index: 1.787
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 6.12±0.23(Predicted)
• Water Solubility: Insoluble in water.
• Sensitive: Air & Light Sensitive
• BRN: 1102552
• CAS DataBase Reference: 3,5-DIIODOSALICYLALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIIODOSALICYLALDEHYDE(2631-77-8)
• EPA Substance Registry System: 3,5-DIIODOSALICYLALDEHYDE(2631-77-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• WGK Germany: 3
• Hazardous Substances Data: 2631-77-8(Hazardous Substances Data)

Usage

Uses

3,5-Diiodosalicylaldehyde is used to synthesize new Schiff bases, (2,4-diiodo-6-[(2-morpholin-4-yl-ethylimino)-methyl]-phenol and 2,4-diiodo-6-[(3-morpholin-4-yl-propylimino)-methyl]-phenol) and the new tridentate ligand, [(2-hydroxy-3,5-diiodo-benzylidene)-amino]-acetic acid (HDBA), 3-bromo-N?-(2-hydroxy-3,5-diiodobenzylidene)benzohydrazide monohydrate.

InChI:InChI=1/C7H4I2O2/c8-5-1-4(3-10)7(11)6(9)2-5/h1-3,11H

Upstream product

• 90-02-8 salicylaldehyde 
• 2234-16-4 1-(2,4-dichlorophenyl)ethan-1-one 
• 89-95-2 2-methyl-benzyl alcohol 
• 22118-09-8 2-bromoacetyl chloride 
• 541-73-1 1,3-Dichlorobenzene 
• 60-29-7 diethyl ether 
• 7732-18-5 water 
• 24123-68-0 2,2-dibromo-1-(2,4-dichlorophenyl)ethanone 
• 121-45-9 phosphorous acid trimethyl ester 
• 598-21-0 2-Bromoacetyl bromide 
• 13094-51-4 bromoacetic anhydride 

Downstream Products

• 21405-37-8 2,4-diiodo-6-(p-tolyliminomethyl)phenol 
• 101883-75-4 6,8-diiodo-3-(4-methoxy-benzoyl)-coumarin 
• 101422-20-2 3-(2-chloro-benzoyl)-6,8-diiodo-coumarin 
• 133-91-5 3,5-diiodosalicylic acid 
• 477339-39-2 (S,E)-2-(((1-hydroxy-3,3-dimethylbutan-2-yl)imino)methyl)-4,6-diiodophenol 
• 255052-10-9 α-(3,5-diiodo-2-hydroxyphenyl)-N-tert-butylnitrone 
• 1187455-43-1 (S)-3-(2-hydroxy-3,5-diiodobenzylideneamino)-4-isopropyl-2-oxazolidinone 
• 1397334-48-3 2-((E)-(((1R,2S)-2-hydroxy-1,2-diphenylethyl)imino)methyl)-4,6-diiodophenol 
• 32024-13-8 3,5-Diiodo-2-methoxybenzaldehyde 

Relevant articles and documents

Synthesis and crystal structure of 2,4-diiodo-6-[(2-morpholin-4-yl- ethylimino)-methyl]-phenolato-zinc(II)

One new complex, 2,4-Diiodo-6-[(2-morpholin-4-yl-ethylimino)- methyl]- phenolato-zinc(II) has been designed and synthesized. The structure was determined by UV, IR and single X-ray crystallography study. The title complex C26H30O4N4I4Zn crystallizes in the triclinic space group P - 1 with the cell parameters a = 9.938(2) A, b = 11.937(2) A, c = 14.527(3) A, α = 87.14(3)°, β = 79.03(3)°, γ = 76.20(3)°, V = 1565.1(5) A3 and Z = 2. The central zinc(II) is four coordinate and bonds to two nitrogen atoms and two oxygen atoms from two 3,5-diiodosalicylaldehyde- 2- morpholinoethylamine Schiff bases. The complex is linked into a column by weak intermolecular interactions.

BuChE-IDO1 inhibitor as well as preparation method and application thereof

The invention relates to the field of medicines, and particularly discloses a BuChE-IDO1 inhibitor as well as a preparation method and application thereof. The 7-chlorine-3-substituted benzothiophene part of sertaconazole is chemically modified, the influence of the 7-chlorine-3-substituted benzothiophene part of sertaconazole on the in-vitro inhibitory activity of AChE, BuChE and IDO1 is explored, the target compound is further optimized, and the technical problems that an existing BuChE-IDO1 inhibitor is poor in pertinence and safety are solved. What is explored is that an appropriate substituent group introduced to a 2-benzothiazole ring can form additional interaction with surrounding amino acids and heme iron, so that the binding affinity of the analogue with BuChE and IDO1 is increased, and a new idea is broadened for more efficient and targeted treatment of advanced AD diseases.

Imidazole compound and preparation method and application thereof, organic solderable protective agent containing imidazole compound and surface treatment method

The invention relates to the technical field of precious metal surface treatment, and in particular, relates to the technical field of copper or copper alloy surface protection materials. The invention discloses a dichlorophenyl imidazole compound, an application of the dichlorophenyl imidazole compound serving as a film forming matter of an organic solderable protective agent, and an organic solderable protective agent. The invention also discloses an application of the compound in copper or copper alloy surface anti-oxidation treatment, and a surface treatment method of the copper or copperalloy, wherein the method comprises the following steps: infiltrating the surface of the copper or copper alloy with the organic weldable protective agent containing the compound, and drying to generate a coating layer on the surface.

Novel thiazole–pyrazolone hybrids as potent ACE inhibitors and their cardioprotective effect on isoproterenol-induced myocardial infarction

A facile synthesis of a group of novel thiazole–pyrazolone hybrids and their investigation for angiotensin-converting enzyme (ACE) inhibition are reported in this study. These compounds were synthesized using a well-known approach, based on the condensation of ethyl acetoacetate with thiazolylhydrazines, and characterized by various spectroscopic and analytical techniques. The entire set of compounds displayed a moderate-to-excellent inhibitory activity against ACE. In particular, compound 4i was found to be the most potent ACE inhibitor and was further studied for cardioprotective effects against isoproterenol (ISO)-induced myocardial infarction (MI) in rats. Compound 4i improved the cardiac function and prevented cardiac injury induced by ISO in Sprague Dawley rats. The levels of oxidative stress and proinflammatory cytokines were also restored to near normal by 4i as compared with the ISO group. In the Western blot analysis, compound 4i prevented mitochondrial apoptosis after MI by downregulating the expression of cleaved caspase-3 and Bax, with the upregulation of Bcl-2, as compared with the ISO group.